All lobbying filings

THE MCMANUS GROUP

Lobbying for AMGEN

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 2

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 839
Safeguarding Honest Speech Act

Lobbying activity 1

Medicare/Medicaid

Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492/S. 839, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.